---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-027432"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-08-21T23:59:59+00:00"
generated_at: "2026-05-31T08:15:43.345574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar receives HREC clearance in Australia for Phase 1 trial of MNPR-101-Lu in advanced cancers

## Summary
- HREC clearance in Australia to commence Phase 1 therapeutic trial of MNPR-101-Lu (Lu-177 with anti-uPAR antibody).
- Trial will enroll patients with advanced solid cancers, including triple negative breast and pancreatic cancer.
- Preclinical data showed complete tumor elimination in human pancreatic cancer xenograft model after single injection.
- MNPR-101-Lu is a therapeutic follow-on to the ongoing MNPR-101-Zr imaging and dosimetry trial.

## SEC filing metadata
- accession: 0001437749-24-027432
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924027432/0001437749-24-027432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924027432/mnpr20240820_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-027432
- JSON: https://secwatch.observer/filing/0001437749-24-027432.json
- Plain text: https://secwatch.observer/filing/0001437749-24-027432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.